---
title: "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR"
description: "Pomerantz Law Firm is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) regarding potential securities fraud by the company and its officers. Following a May 20"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252339374.md"
published_at: "2025-08-09T14:50:43.000Z"
---

# INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

> Pomerantz Law Firm is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) regarding potential securities fraud by the company and its officers. Following a May 2025 FDA meeting announcement, Capricor's stock fell 29.13%. A subsequent report in June 2025 about the cancellation of an advisory committee meeting led to a further 30.82% drop in stock price. Investors are encouraged to contact Pomerantz for more information.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Capricor and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

**\[Click here for information about joining the class action\]**

On May 5, 2025, Capricor issued a press release announcing that after “the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company’s Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy”, the FDA had “confirmed its intent to hold an advisory committee meeting” in connection with the BLA.

On this news, Capricor’s stock price fell $3.00 per share, or 29.13%, to close at $7.30 per share on May 6, 2025.

Then, on June 20, 2025 the publication STAT reported that the new head of the relevant FDA unit had canceled the advisory committee meeting for deramiocel due to uncertainty about the drug’s efficacy and safety.

On this news, Capricor’s stock price fell $3.68 per share, or 30.82%, to close at $8.26 per share on June 20, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

**CONTACT:**  
Danielle Peyton  
Pomerantz LLP  
dpeyton@pomlaw.com  
646-581-9980 ext. 7980

### Related Stocks

- [CAPR.US - Capricor Therap](https://longbridge.com/en/quote/CAPR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Capricor Therapeutics 發佈投資者演示，重點介紹杜氏肌營養不良症項目和外泌體平台 | Capricor Therapeutics Inc. 發佈了一份投資者演示文稿，詳細介紹了其杜氏肌營養不良症治療項目 deramiocel 的最新進展。主要亮點包括完成了預許可檢查、HOPE-3 第三階段試驗的積極結果，以及計劃向 FDA  | [Link](https://longbridge.com/en/news/274992906.md) |
| Capricor 治療公司（納斯達克股票代碼：CAPR）的空頭頭寸減少了 69.4% | Capricor Therapeutics, Inc.（納斯達克代碼：CAPR）在 12 月份的空頭頭寸減少了 69.4%，賣空股份總計為 5,029,282 股。該股票開盤價為 29.29 美元，52 周最高價為 40.37 美元。分析師 | [Link](https://longbridge.com/en/news/270785955.md) |
| BUZZ-Capricor 股價上漲，因 FDA 要求提供更多數據但無需進行新的試驗以用於杜氏肌營養不良症療法 | Capricor Therapeutics 的股票在盤前交易中上漲 6.4%，至 25.90 美元，此前 FDA 要求提供其杜氏肌營養不良症治療藥物 deramiocel 的額外文件，但並未要求進行新的試驗。該公司計劃在 2 月份提交完整的 | [Link](https://longbridge.com/en/news/273099287.md) |
| FDA 要求提供更多 HOPE-3 數據以審查 Capricor 治療的 Deramiocel 的批准 | Capricor Therapeutics Inc. 正在應對其生物製品許可申請（Biologics License Application）中關於 Deramiocel 的監管挑戰，Deramiocel 是一種用於杜氏肌營養不良症的細胞療 | [Link](https://longbridge.com/en/news/273097591.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
